-
-
-
-
-
-
-
Kymera presents preclinical lupus data for oral IRF5 degrader KT-579
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $103 at RBC Capital
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $116 at Wells Fargo
-
-
-
-
-
-
-
Kymera Therapeutics starts phase 2b atopic dermatitis trial
-
-
-
-
-
-
-
Kymera presents preclinical data for oral IRF5 degrader KT-579
-
428,611 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

